Complete Guide to Infigratinib Pharmacokinetics
Overview
Infigratinib is a Small Molecule used in the Oncology therapeutic area. It is indicated for Cholangiocarcinoma. Population PK simulator for infigratinib FGFR inhibitor. Explore dosing in cholangiocarcinoma with FGFR2 fusions.
Mechanism of Action
Infigratinib exerts its pharmacological effect by targeting FGFR1-3. As a Small Molecule, it modulates this target to achieve therapeutic efficacy in Cholangiocarcinoma. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK models for Infigratinib:
| Parameter | Value |
|---|---|
| ka | 0.3 h-1 |
| CL F | 33.1 L/h |
| Tmax | 6 h |
| Vc F | 400 L |
| Vp F | 1200 L |
| half life | 33.5 h |
| bioavailability | 32% |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Infigratinib is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of Cholangiocarcinoma, understanding the pharmacokinetics of Infigratinib is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Infigratinib pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Infigratinib PK Simulator
Explore Infigratinib pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Infigratinib?
The elimination half-life of Infigratinib depends on patient-specific factors. Based on published models, the typical half-life is approximately 33.5 h.
How is Infigratinib administered?
Infigratinib is administered via the Oral route. It is indicated for Cholangiocarcinoma. As a Small Molecule, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Infigratinib?
Key pharmacokinetic parameters for Infigratinib include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Infigratinib dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Infigratinib PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.